Arcutis Biotherapeutics, Inc.
ARQT
Rang in aandelen
#4366
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aandeelprijs
$28.54
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$3.59B
Verandering (1 dag)
-1.94%
Verandering (1 jaar)
36.66%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Categorie
Healthcare
EPS voor Arcutis Biotherapeutics, Inc. (ARQT)
EPS per June 2026 TTM: $0.22
Volgens de laatste financiële rapporten en de aandelenkoers van Arcutis Biotherapeutics, Inc. is de huidige EPS van het bedrijf (TTM) $0.22. Eind 2023 had het bedrijf een EPS van $-3.78, een daling ten opzichte van de EPS van 2022 die $-5.66 bedroeg.
EPS-geschiedenis van Arcutis Biotherapeutics, Inc. van 2017 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.22 | -118.97% |
| 2024 | $-1.16 | -69.31% |
| 2023 | $-3.78 | -33.22% |
| 2022 | $-5.66 | 35.73% |
| 2021 | $-4.17 | 9.74% |
| 2020 | $-3.80 | 245.45% |
| 2019 | $-1.10 | 107.55% |
| 2018 | $-0.53 | -88.75% |
| 2017 | $-4.71 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | 7,772.73% |
US
|
|
| $-7.98 | -3,727.27% |
US
|
|
| $-5.29 | -2,504.55% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 12,509.09% |
NL
|
